AlgiPharma announces two new positions avaliable. AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. Preference will be given to those candidates already resident in Norway or who are already eligible to work in Norway. The deadline for applications is the 12th May 2019 […]
AlgiPharma has started preparations for two new clinical phase 2b trials in cystic fibrosis patients.
AlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”.
Building on the previous success with the AlgiFerm project, AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), FMC Biopolymer, and SINTEF have secured additional funding from the UK’s Technology Strategy Board (now Innovate UK) and Innovation Norway for further investigation on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG. The study will focus on developing methods for scaling-up microbial fermentation production of OligoG at CPI.
The collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has been successful in achieving the project milestones.
AlgiPharma has been awarded a four year grant from the Norwegian Research Council for the project “Tailored OligoG in the treatment of chronic infectious biofilms”.
A collaboration project initiated by AlgiPharma, together with leading experts in fermentation at the Centre for Process Innovation (CPI, Redcar, UK), has secured funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for a feasibility study on microbial production of AlgiPharma’s promising new alginate oligomer drug candidate, OligoG.
Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, Onsøyen E, Myrvold R, Hill KE, Thomas DW. Biofouling. 2013 Apr;29(4):413-21. doi: 10.1080/08927014.2013.777954. External link to Pubmed.gov Abstract The influence of a novel, safe antibiofilm therapy on the mechanical properties of Pseudomonas aeruginosa and Acinetobacter baumannii biofilms in vitro was characterized. A multiscale approach employing […]
In collaboration with leading experts in fermentation at the Centre for Process Innovation (CPI, Newcastle, UK), Algipharma has secured combined funding (2.700.000 NOK) from the UK’s Technology Strategy Board and Innovation Norway for pilot scale studies for production of its promising new alginate oligomer drug candidate.
AlgiPharma is part of a multi-disciplinary consortium that has been awarded funding from the Research Council of Norway (NANO2021 programme).
